Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals — Neotherapeutics — Shareholder Meeting (June 2002)

66 slides from Spectrum Pharmaceuticals's shareholder meeting presentation, Jun 18, 2002

  1. Slide 1: June 17, 2002

    June 17, 2002

  2. Slide 2: Presenters: Glasky, Shrotriya, Gulko

    Alvin J. Glasky, Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer Rajesh C. Shrotriya, M.D. President, Chief Operating Officer Sam Gulko Senior Vice President of Finance, Chief Financial Officer

  3. Slide 3: Forward-looking statements

    This presentation contains forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the early stage of product development,

  4. Slide 4: 2001 Annual Stockholders Meeting

    2001 Annual Stockholders Meeting Where are we? Where are we going? How will we get there?

  5. Slide 5: Financial Update

    Sam Gulko Senior Vice President of Finance, Chief Financial Officer, Secretary and Treasurer Financial Update

  6. Slide 6: Income Statement Data, Fiscal Year

    Income Statement Data Fiscal year ended December 31: (in thousands except per share data) 2001 2000 1999 Revenues $ 41 $ -- $ -- Operating Expenses Research & Development $ 20,611 $ 38,767 $ 20,058 General and Administrative $ 7,580 $ 5,107 $ 5,924 Loss From Operations $ (28,150) $ (43,874) $ (25,98

  7. Slide 7: Income Statement Data, Three Months Ended March 31

    Income Statement Data Three months ended March 31: (in thousands except per share data) 2002 2001 2000 Revenues $ 20 $ -- $ -- Operating Expenses Research & Development $ 4,924 $ 3,807 $ 8,500 General and Administrative $ 1,479 $ 1,801 $ 955 Loss From Operations $ (6,383) $ (5,608) $ (9,455) Other I

  8. Slide 8: Balance Sheet

    Balance Sheet (in thousands) 3/31/02 12/31/01 Cash and Marketable $ 5,812 $ 7,157 Securities Working Capital $ 2,128 $ 2,805 Total Assets $ 10,923 $ 12,825 Total Liabilities $ 4,560 $ 6,038 Minority Interest In Consolidated Subsidiaries $ - $ - Shareholder's Equity $ 6,362 $ 6,787

  9. Slide 9: 2002 Financings

    2002 Financings March, 2002 Common Stock with Warrants $ 6.2 million June, 2002 Common Stock with Warrants $ 1.7 million Total $ 7.9 million

  10. Slide 10: Fully Diluted Common Shares

    Fully Diluted Common Shares June 14, 2001 Issued and Outstanding (50,000,000 Authorized) 33,647,434 Investor Warrants, Stock Options, etc. 8,553,340 Potential total fully diluted common shares 42,200,774

  11. Slide 11: Actual and Projected Burn Rate

    2000 2001 1Q-2002 Q2-2002 Q3-2002 Q4-2002 Burn Rate 4.1 2.3 2.1 1.6 0.9 0.9 Actual and Projected Burn Rate Burn Rate in $ Millions Projected Actual

  12. Slide 12: NeoTherapeutics' Technology Assets

    Alvin J. Glasky, Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer Rajesh C. Shrotriya, M.D. President, Chief Operating Officer NeoTherapeutics' Technology Assets

  13. Slide 13: NeoTherapeutics' Technology Assets

    NeoTherapeutics' Technology Assets Solid Technology Foundation Neurology Functional Genomics Generics (NeoJB) Oncology

  14. Slide 14: Neurology Division

    Discovers and Develops Novel Patented Drugs Neurology Division NEUROLOGY DIVISION

  15. Slide 15: Neurology

    Neurology Neotrofin(tm) Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy

  16. Slide 16: Neotrofin in Parkinson's Disease

    Neotrofin in Parkinson's Disease

  17. Slide 17: Neotrofin in Parkinson's Disease Study Design

    Neotrofin in Parkinson's Disease Study Design Stable Parkinson's disease patients Double blind (24 Neotrofin, 6 Placebo) 2 weeks at 250 mg twice daily, then 2 weeks at 500 mg twice daily, then 8 weeks at 1,000 mg twice daily Follow-up for 4 weeks with no treatment

  18. Slide 18: Neotrofin in Chemotherapy-Induced Neuropathy

    Neotrofin in Chemotherapy- Induced Neuropathy

  19. Slide 19: Neotrofin: Neuropathy Data

    30 32 34 36 38 40 42 44 46 48 50 Day 17 Control Vincristine Vincristine +Neotrofin 30mg Sensory Nerve Conduction Rate (m/sec) Data Source: AACR-NCI-EORTC Poster Neotrofin has neuroprotective and neuroregenerative effects on sensory nerve conduction responses in chemo- induced neuropathy model in rat

  20. Slide 20: Neurology

    Neurology AIT-034 Dementia NEO-339 Attention Deficit Hyperactivity Disorder Mild Cognitive Impairment Neotrofin Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy

  21. Slide 21: NEO-339 in Attention Model

    Neurology NEO-339 in Attention Model

  22. Slide 22: Neurology Antipsychotic Platform

    Neurology Neotrofin Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy AIT-034 Dementia NEO-339 Attention Deficit Hyperactivity Disorder Mild Cognitive Impairment Antipsychotic Platform (AP Platform) Multiple Therapeutic Targets Schizophrenia Depression Parkinson's Disease Analge

  23. Slide 23: Importance of Antipsychotic Drugs

    Importance of Antipsychotic Drugs Market size in 2001: Sales = $7.7 Billion Antipsychotics are 2% of all global pharmaceutical sales Market grew 30% in 2001 Olanzapine (Zyprexa) $ 3.1 Billion Clozapine (Clozaril) $ 1.0 Billion Risperidone (Risperdal) $ 1.8 Billion Others (Haldol, Seroquel, etc.) $ 1

  24. Slide 24: Neurology Antipsychotic Platform

    Neurology Antipsychotic Platform Efficacy is based upon a therapeutic balance between dopamine and serotonin neurotransmitter systems without effecting other receptors.

  25. Slide 25: Antipsychotic Platform: Neurotransmitter Balance

    Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Therapeutic Effect Receptors Dopam

  26. Slide 26: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  27. Slide 27: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  28. Slide 28: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  29. Slide 29: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  30. Slide 30: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  31. Slide 31: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  32. Slide 32: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  33. Slide 33: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  34. Slide 34: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  35. Slide 35: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  36. Slide 36: Antipsychotic Platform: Neurotransmitter Balance

    Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop

  37. Slide 37: NEO-376 Does Not Produce Memory Disruption

    NEO-376 Does Not Produce Memory Disruption

  38. Slide 38: Antipsychotic Technology Platform

    Eight compounds evaluated Receptor binding profile different than marketed antipsychotics Minimal to no cognitive impairment Minimal side effects predicted Improved toxicology profile Antipsychotic Technology Platform

  39. Slide 39: Antipsychotic Technology Platform

    Antipsychotic Technology Platform These compounds represent a new generation of antipsychotic therapy

  40. Slide 40: NeoGene Technologies: Functional Genomics

    Functional Genomics Technology to Identify Targets for Drug Development NeoGene Technologies Slide 85

  41. Slide 41: NeoGene Technologies, Inc. Highlights

    NeoGene Technologies, Inc. Two Pfizer alliances in 2001: $300,000 Milestone payments so far in 2002: $250,000 Recent publications 4 (1 pending) Highlights Slide 87

  42. Slide 42: NeoJB

    Manufacturing and Development of Patented and Generic Drugs and Over-the-counter Products NeoJB Slide 89

  43. Slide 43: NeoJB Products

    NeoJB Ciprofloxacin broad spectrum antimicrobial Ofloxacin broad spectrum antimicrobial Fluconazole antifungal Slide 91

  44. Slide 44: NeoJB

    NeoJB NeoJB is pursuing regulatory development of established products from India-based manufacturing sites Minimal financial resources are required at this time to further these efforts Slide 93

  45. Slide 45: NeoOncoRx

    Development and Commercialization of Late-Stage Anti-Cancer Drugs NeoOncoRx Slide 95

  46. Slide 46: Oncology Products

    Oncology Products Satraplatin Neoquin Elsamitrucin Slide 97

  47. Slide 47: Elsamitrucin: Non-Hodgkin's Lymphoma

    Elsamitrucin: Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma 44,000 Phase 1 Phase 2 Phase 3 NDA New Cases/Year Source: UBS Warburg Estimated Market Size > $1 Billion Slide 99

  48. Slide 48: Oncology Elsamitrucin Phase Trials

    Oncology Elsamitrucin Phase 1 Slide 101 Phase 2 Trials completed Colorectal Ovarian Breast Lung Non-Hodgkins Lymphoma 3 trials completed

  49. Slide 49: Elsamitrucin Phase 2 study

    Data Source: Bristol Myers Squibb Non-Hodgkin's Lymphoma Phase 2 study in 31 refractory patients 60% of patients had failed two or more prior treatment regimens 25% of patients showed an objective response Improved side effect profile Oncology Elsamitrucin Slide 103

  50. Slide 50: Neoquin: Bladder Cancer

    Neoquin(tm) : Bladder Cancer Bladder Cancer 54,400 Phase 1 Phase 2 Phase 3 NDA New Cases/Year Source: Oncology, May 2000 Estimated Market Size > $300 Million Slide 105

  51. Slide 51: Oncology Satraplatin

    Oncology Satraplatin Slide 107

  52. Slide 52: Satraplatin: Advantages

    Satraplatin : Advantages Outpatient Hospital Home Convenience Short IV infusion Prolonged IV infusion Oral Administration - - +++ $$ Satraplatin ++ ++ Cross-resistance In-vitro +++ +++ Activity / Efficacy $600+ million $200 million Sales Carboplatin Cisplatin Slide 109

  53. Slide 53: Satraplatin: Prostate Cancer

    Satraplatin: Prostate Cancer In a 50 patient phase 3 study, satraplatin shows a survival advantage over the current therapy Prednisone + Satraplatin Prednisone Data Source: Bristol Myers Squibb Slide 111

  54. Slide 54: NeoTherapeutics' Patents

    NeoTherapeutics' Patents

  55. Slide 55: NeoTherapeutics' U.S. Patent Status

    NeoTherapeutics' U.S. Patent Status Issued Allowed Pending Total Neurology 9 1 16 26 Genomics 1 - 4 5 Oncology 6 - 1 7 (in-licensed) Corresponding foreign patents have been either issued or are pending

  56. Slide 56: Summary of NeoTherapeutics' Technology Assets

    Summary of NeoTherapeutics' Technology Assets Neotrofin(tm) - Parkinson's Disease Neotrofin(tm) - Chemotherapy-Induced Neuropathy Neotrofin(tm) - Spinal Cord Injury AIT-034 - Dementia NEO-339 - Attention Deficit Hyperactivity Disorder NEO-339 - Mild Cognitive Impairment AP Platform - Schizophrenia A

  57. Slide 57: 2001 Annual Stockholders Meeting

    2001 Annual Stockholders Meeting Where are we going? Where are we?

  58. Slide 58: Where are we going?

    Where are we going? Complete ongoing low-cost studies Parkinson's Disease Chemotherapy-Induced Neuropathy Spinal Cord Injury Out-licensing Co-development (partnership) Satraplatin clinical development (upon receipt of capital) Initiate phase 3 clinical trial in prostate cancer Initiate three phase 2

  59. Slide 59: How will we get there?

    2001 Annual Stockholders Meeting How will we get there? Where are we going? Where are we?

  60. Slide 60: What are our strategic plans going forward?

    What are our strategic plans going forward? Out-license products Co-development partnerships Cash financing through Investors Sale of divisions Merge the entire Company

  61. Slide 61: Summary

    Slide 64 Summary

  62. Slide 62: It has been a tough quarter, but upside remains

    It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains...

  63. Slide 63: It has been a tough quarter, but upside remains

    It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms

  64. Slide 64: It has been a tough quarter, but upside remains

    It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms Our challenge is to gain realization and recognition of this value in the marketplace

  65. Slide 65: It has been a tough quarter, but upside remains

    It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms Our challenge is to gain realization and recognition of this value in the marketplace

  66. Slide 66: Slide

    Slide 63

Neotherapeutics — Shareholder Meeting (June 2002) on 6ix